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Abstract
Prostatic acid phosphatase (PAP) is expressed in nociceptive neurons and functions as an ectonucleotidase. When injected
intraspinally, the secretory isoforms of human and bovine PAP protein have potent and long-lasting antinociceptive effects
that are dependent on A1-adenosine receptor (A1R) activation. In this study, we purified the secretory isoform of mouse
(m)PAP using the baculovirus expression system to determine if recombinant mPAP also had antinociceptive properties. We
found that mPAP dephosphorylated AMP, and to a much lesser extent, ADP at neutral pH (pH 7.0). In contrast, mPAP
dephosphorylated all purine nucleotides (AMP, ADP, ATP) at an acidic pH (pH 5.6). The transmembrane isoform of mPAP
had similar pH-dependent ectonucleotidase activity. A single intraspinal injection of mPAP protein had long-lasting (three
day) antinociceptive properties, including antihyperalgesic and antiallodynic effects in the Complete Freund’s Adjuvant
(CFA) inflammatory pain model. These antinociceptive effects were transiently blocked by the A1R antagonist 8-cyclopentyl-
1, 3-dipropylxanthine (CPX), suggesting mPAP dephosphorylates nucleotides to adenosine to mediate antinociception just
like human and bovine PAP. Our studies indicate that PAP has species-conserved antinociceptive effects and has pH-
dependent ectonucleotidase activity. The ability to metabolize nucleotides in a pH-dependent manner could be relevant to
conditions like inflammation where tissue acidosis and nucleotide release occur. Lastly, our studies demonstrate that
recombinant PAP protein can be used to treat chronic pain in animal models.
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Introduction
Small-diameter dorsal root ganglia (DRG) neurons contain a
classic, histochemically-defined enzyme known as Fluoride-Resis-
tant Acid Phosphatase (FRAP) or Thiamine Monophosphatase
(TMPase) [1,2]. Recently, we found that TMPase was molecularly
equivalent to Prostatic Acid Phosphatase (PAP, also known as
ACPP) [3]. In mammals, PAP is expressed as a secreted protein or
as a transmembrane protein [4,5,6]. These isoforms have identical
N-terminal regions, including a signal peptide and extracellular
acid phosphatase domain, but differ at the C-terminus due to the
inclusion or exclusion of a transmembrane domain. Using in situ
hybridization with isoform-specific riboprobes, we found that
small-diameter DRG neurons primarily express the transmem-
brane isoform of PAP [3]. Moreover, using immunohistochemis-
try, we found that PAP protein is localized to a majority of all
nonpeptidergic nociceptive neurons, a subset of peptidergic
nociceptive neurons and to axon terminals located in lamina II
of the dorsal spinal cord [3].
We also found that PAP functions in nociceptive circuits as an
ectonucleotidase by dephosphorylating adenosine monophosphate
(AMP) to adenosine [3]. This was based on our observation that
intrathecal injection of human (h)PAP protein (the secreted
isoform) produced long-lasting antinociceptive, antihyperalgesic
and antiallodynic effects that were dependent on A1-adenosine
receptor (A1R) activation [3]. These antinociceptive effects were
eight-times more effective than the commonly used analgesic
morphine. When injected intrathecally, bovine (b)PAP also had
long-lasting antinociceptive effects that were dependent on A1R
activation. Conversely, PAP knockout (PAP2/2) mice showed
enhanced sensitivity in animal models of chronic inflammatory
pain and neuropathic pain [3], a phenotype that was similar to
A1R
2/2 mice [7]. Lastly, dephosphorylation of extracellular AMP
was greatly reduced in small-diameter DRG neurons and dorsal
spinal cord of PAP2/2 mice.
For our initial study, we used secretory isoforms of PAP that
were purified from human seminal fluid and from bovine prostate
[3]. The secretory isoforms of human, bovine and mouse PAP are
,80% identical to one another at the amino acid level (based on
pairwise sequence comparisons), suggesting they might have
similar antinociceptive effects in vivo. At the time we performed
our initial studies, we were unable to test mPAP protein for
antinociceptive effects because there were no commercially
available sources of pure mPAP protein. Moreover, without pure
protein, we could not determine the substrate specificity for
secretory mPAP. To overcome these limitations, we synthesized
and purified recombinant mPAP protein (secretory isoform).
Strategies for generating recombinant human and rat PAP protein
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were previously described [8,9]. At neutral pH, mPAP primarily
dephosphorylated AMP. In addition, we found that mPAP could
dephosphorylate all purine nucleotides (AMP, ADP, ATP) under
acidic pH conditions. This suggested a broader function for PAP
in nucleotide metabolism and has implications in inflammatory
pain conditions where extracellular pH is reduced.
Recombinant proteins can be produced in large quantities, are
not likely to be contaminated with human pathogens and can be
used in humans [10,11,12]. Thus, the approaches outlined in this
study could be used to purify and test recombinant mouse or
human PAP as a treatment for chronic pain in humans.
Results
Purification of recombinant mPAP using the baculovirus
expression system
Large quantities of recombinant human or rat PAP (secretory
isoform) can be generated in yeast or baculovirus expression
systems [8,9]. We generated a baculovirus expression construct
containing the entire open-reading frame of secretory mPAP,
encompassing the signal peptide (SP) and catalytic domain fused to
a C-terminal thrombin-hexahistidine (Tr-H6) epitope tag (Fig. 1A,
B). Although the thrombin cleavage site can be used to efficiently
remove the epitope tag (Fig. 1B, data not shown), we performed
our studies below with recombinant mPAP-Tr-H6 (henceforth
referred to as mPAP) containing the C-terminal epitope tag
because removal of the tag required additional purification steps
and did not impact enzyme activity.
We detected large quantities of mPAP protein in the tissue
culture supernatant of Hi5 insect cells two days after infection with
recombinant baculovirus. We purified mPAP from the superna-
tant in one step, using nickel chelate affinity chromatography. We
confirmed protein purity by running mPAP on an SDS-PAGE gel
and staining for total protein (Fig. 1C) and western blotting
(Fig. 1D). In both cases, we observed one predominant band at
,45 kDa, corresponding to the calculated molecular weight of
monomeric mPAP (45.2 kDa). The weakly stained ,90 kDa band
on our overloaded western blot likely reflects a small amount of
non-denatured mPAP, consistent with the fact that native PAP is a
dimer [13,14]. No additional bands were observed, indicating that
mPAP protein was pure and largely intact. This purified,
recombinant mPAP protein effectively dephosphorylated the
generic acid phosphatase substrates para-nitrophenyl phosphate
(p-NPP) and 6,8-difluoro-4-methylumbelliferyl phosphate
(DiFMUP) and was inhibited by the acid phosphatase inhibitor
L-(+)-tartrate (IC50 = 1.45 mM; Fig. 2). Recombinant human and
rat PAP are similarly inhibited by L-(+)-tartrate [8,9,15].
Recombinant mPAP dephosphorylates purine
nucleotides in a pH-dependent manner
We previously found that hPAP (secreted isoform) generated
adenosine by dephosphorylating AMP and, to a much lesser
extent, ADP at neutral pH [3]. To determine if secretory mPAP
had similar substrate specificity and to evaluate pH dependence,
we incubated mPAP with AMP, ADP or ATP at pH 7.0 or
pH 5.6, then detected inorganic phosphate using the malachite
green assay. We found that mPAP dephosphorylated AMP and, to
a lesser extent, ADP at neutral pH (Fig. 3A), consistent with our
previous findings using hPAP [3]. At pH 5.6, mPAP dephosphor-
ylated AMP and ADP, and to a lesser extent, ATP (Fig. 3B). This
latter finding was consistent with a previous study showing that
secretory hPAP could dephosphorylate all nucleotides under acidic
conditions with a rank order AMP.ADP.ATP [16].
We previously found that the transmembrane isoform of mouse
PAP (TM-PAP) could dephosphorylate extracellular AMP at
pH 5.6 using enzyme histochemistry, indicating that PAP had
ectonucleotidase activity [3]. At the time, we did not test hydrolysis
at neutral pH or hydrolysis of other nucleotides. To determine if
TM-PAP could dephosphorylate additional nucleotides extracel-
lularly, and if dephosphorylation was pH dependent, we
transfected mouse TM-PAP into HEK 293 cells and stained
non-permeabilized cells using enzyme histochemistry. Use of non-
permeabilized cells allowed us to measure extracellular nucleotide
hydrolysis in a cellular context. At pH 7.0, TM-PAP transfected
cells were heavily stained using AMP as substrate and much less
intensely stained using ADP as substrate (Fig. 4A–C). At pH 5.6,
TM-PAP transfected cells were heavily stained using AMP and
moderately stained using ADP as substrate (Fig. 4D–F). Control
cells transfected with the fluorescent protein Venus were not
Figure 1. Purification of recombinant mPAP. (A) A thrombin
cleavage site (Tr) followed by hexahistidine tag (H6) and stop codon (*)
were added to the C-terminus of the secretory isoform of mPAP.
SP = signal peptide of mPAP. Map is not drawn to scale. (B) Amino acid
sequence at the junction between the catalytic domain and Tr-H6 tag.
Arrow marks thrombin cleavage site. Asterisk marks stop codon. (C)
GelCode blue-stained SDS-PAGE gel and (D) western blot of purified
recombinant mPAP protein (1 mg and 5 mg, respectively). The western
blot was probed with an anti-hexahistidine antibody.
doi:10.1371/journal.pone.0004248.g001
Figure 2. Inhibition of mPAP by L-(+)-tartrate. The indicated
concentrations of L-(+)-tartrate were added to reactions (n = 3 per
concentration) containing mPAP (1 U/mL), 100 mM sodium acetate,
pH 5.6 and the fluorescent acid phosphatase substrate DiFMUP.
Relative fluorescence units (RFU). All data are presented as mean-
s6s.e.m. Prism 5.0 (GraphPad Software, Inc) was used to generate
curve.
doi:10.1371/journal.pone.0004248.g002
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intensely stained under any of the conditions examined (Fig. 4G–
L). When taken together, these data suggest TM-PAP has pH-
dependent ectonucleotidase activity, with AMP being the
preferred substrate at neutral pH and AMP and ADP being
substrates at acidic pH. Moreover, these data suggest PAP could
generate adenosine following hydrolysis of AMP, ADP or ATP
under acidic pH conditions [3].
Recombinant mPAP has long-lasting antinociceptive
properties
A single intrathecal injection of hPAP protein (secreted isoform)
has antinociceptive, antihyperalgesic and antiallodynic effects that
last for three days [3]. To determine if mPAP also had long-lasting
antinociceptive effects, we intrathecally (i.t.) injected wild-type mice
with two doses of recombinant mPAP protein (Fig. 5). Control mice
were injected i.t. with heat-denatured, and hence phosphatase-
inactive, mPAP. We then measured noxious thermal and
mechanical sensitivity before (baseline, BL) and after mPAP
injections. Six hours after i.t. injection, paw withdrawal latency to
the noxious thermal stimulus was significantly increased relative to
controls and remained elevated for three days (Fig. 5A). This
antinociceptive effect was dose-dependent and required catalytic
activity, as evidenced by loss of antinociception upon heat-
inactivation of mPAP (Fig. 5A). Active mPAP did not alter
mechanical sensitivity (Fig. 5B) nor did it cause paralysis or sedation.
We next tested mPAP for antihyperalgesic and antiallodynic
effects using the CFA inflammatory pain model. To do this, we
injected CFA into one hindpaw to induce inflammation and used
the non-inflamed paw as a control. Intrathecal injection of mPAP
produced a significant increase in withdrawal latency to the
noxious thermal stimulus (relative to latency on Day 1, pre-
injection) in the inflamed paw (Fig. 6A, white open circles). This
antihyperalgesic effect persisted for three days. mPAP also caused
a significant increase in paw withdrawal latency in the non-
inflamed paw (Fig. 6A, grey open circles, relative to day 1 values),
reproducing results presented in Fig. 5A. In addition, mPAP
produced a significant increase in withdrawal threshold to the
mechanical stimulus (relative to latency on Day 1, pre-injection)
only in the inflamed paw (Fig. 6B, white open circles). This
antiallodynic effect lasted for three days.
mPAP acts through A1Rs to mediate antinociception
The antinociceptive, antihyperalgesic and antiallodynic effects of
hPAP are dependent on A1R activation [3]. Since our biochemical
experiments suggested that mPAP could generate adenosine by
dephosphorylating nucleotides, we next evaluated whether mPAP
had antinociceptive properties that were dependent on A1R
activation. To do this, we injected a second group of CFA-inflamed
mice with the selective A1R antagonist 8-cyclopentyl-1, 3-dipropyl-
xanthine (CPX; 1 mg/kg i.p.). CPX transiently antagonized all
antinociceptive effects of mPAP, including the antihyperalgesic
(Fig. 6A) and antiallodynic (Fig. 6B) effects. This same i.p. dose of
CPX did not affect thermal or mechanical sensitivity in the control or
CFA-inflamed paw once the antinociceptive effects of PAP wore off
(see Figure S10 in [3]). Taken together, these data suggest that the
antinociceptive effects of mPAP were due to ectonucleotidase-
dependent generation of adenosine followed by activation of A1Rs.
Discussion
We previously found that PAP was expressed in nociceptive
neurons and functioned as an ectonucleotidase by dephosphory-
Figure 3. mPAP dephosphorylates purine nucleotides in a pH-
dependent manner. Plot of initial velocity at the indicated
concentrations of AMP, ADP and ATP at (A) pH 7.0 and (B) pH 5.6.
Reactions (n = 3 per point) were stopped after 3 min. Inorganic
phosphate was measured using malachite green. All data are presented
as means6s.e.m. Error bars are obscured due to their small size.
doi:10.1371/journal.pone.0004248.g003
Figure 4. TM-PAP dephosphorylates extracellular purine
nucleotides in a pH-dependent manner. HEK 293 cells were
transfected with expression vectors containing (A–F) mouse TM-PAP or
(G–L) the fluorescent protein Venus as a control. Cells were then
histochemically stained using AMP, ADP or ATP (each 6 mM) as
substrate at pH 7.0 or pH 5.6. Cells were not permeabilized with
detergent. Scale bar (bottom right panel), 50 mm for all panels.
doi:10.1371/journal.pone.0004248.g004
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lating AMP to adenosine. Moreover, PAP had antinociceptive
properties that were dependent on A1R activation [3]. At the time,
we could not perform in vivo gain-of-function studies with mPAP
because there were no commercially available sources of secretory
mPAP protein. To overcome this limitation, we generated and
purified recombinant mPAP protein and then studied the
biochemical properties of mPAP and the effects of mPAP on pain
sensitivity.
Our studies revealed that recombinant mPAP has very similar
biochemical properties when compared to PAP from other
mammalian species, including human [8,13]. Both mPAP and hPAP
are inhibited by L-(+)-tartrate (Fig. 2), both predominantly
dephosphorylate AMP at neutral pH (Fig 3A; [3]) and both
dephosphorylate all adenine nucleotides (with relative activity
AMP.ADP.ATP) at acidic pH (Fig. 3B) [16]. The Km values
(0.9–1.6 mM) we obtained for mPAP using AMP as substrate were
within the range of Km values (0.37–2 mM) reported for hPAP using
AMP as substrate [17,18,19]. Mouse TM-PAP also dephosphorylat-
ed extracellular adenine nucleotides in a pH-dependent manner,
although ATP was not a substrate for TM-PAP as it was for secretory
PAP. This substrate discrepancy could reflect biochemical differences
between these isoforms. Or, more likely, this reflects reduced
sensitivity of the histochemical assay relative to the in vitro enzyme
assay. When taken together, our findings suggest PAP functions as an
ecto-59-nucleotidase (with relative selectivity for AMP) at neutral pH
and as a generic ectonucleotidase (with selectivity for AMP, ADP and
ATP) at acidic pH.
This pH-dependent hydrolysis of purine nucleotides is intrigu-
ing, especially when considering that tissue injury produces an
‘‘inflammatory soup’’ containing protons and nucleotides [20].
Protons produce tissue acidosis, modulate the capsaicin receptor
TRPV1 and activate acid-sensing ion channels (ASICs) half-
maximally at pH values ranging from 4.9 to 6.8 [21,22,23]. ATP
and ADP activate purinergic P2X and P2Y receptors [24,25].
Stimulation of these diverse receptors sensitizes nociceptive
neurons, activates spinal microglia and causes pain
[24,26,27,28,29]. PAP is extensively co-localized with the ATP
receptor P2X3 and is co-localized in 14.4% of all TRPV1+ DRG
Figure 5. Dose-dependent antinociceptive effects of intrathecal mPAP. (A) Effects of increasing amounts of mPAP on paw withdrawal
latency to a radiant heat source. (B) Paw withdrawal threshold to a semi-flexible tip mounted on an electronic von Frey apparatus. (A, B) BL = Baseline.
Injection (i.t.) volume was 5 mL. n = 8 wild-type mice were used per dose. There were significant differences over time between mice injected with
heat-inactivated (0 U) mPAP and mice injected with active (1 U or 2 U) mPAP (Repeated measure two-way ANOVA; P,0.0001 for each dose). Post-
hoc paired t-tests were used to compare responses at each time point between mice injected with active mPAP to mice injected with heat-
inactivated mPAP (** P,0.005; *** P,0.0005). For the heat-inactivated mPAP control, the protein concentration was equivalent to the maximum 2 U
dose of mPAP (1.1 mg/mL). All data are presented as means6s.e.m.
doi:10.1371/journal.pone.0004248.g005
Figure 6. The antinociceptive effects of mPAP can be transiently inhibited with a selective A1R antagonist. Wild-type mice were tested
for (A) noxious thermal and (B) mechanical sensitivity before (baseline, BL) and following injection of CFA (CFA-arrow) into one hindpaw. The non-
inflamed hindpaw served as control. All mice were injected with active mPAP (mPAP-arrow; 2 U, i.t.). Two days later, half the mice were injected with
vehicle (CPX/V-arrow, circles; intraperitoneal (i.p.); 1 hr before behavioral measurements) while the other half were injected with 8-cyclopentyl-1, 3-
dipropylxanthine (CPX/V-arrow, squares; 1 mg/kg i.p.; 1 hr before behavioral measurements). There were significant differences over time between
mice injected with vehicle and mice injected with CPX (Repeated measure two-way ANOVA; P,0.01). Post-hoc paired t-tests were used to compare
responses at each time point between vehicle (n = 10) and CPX-injected mice (n = 10); same paw comparisons. *** P,0.0005. All data are presented as
means6s.e.m.
doi:10.1371/journal.pone.0004248.g006
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neurons in the mouse [3]. Since PAP protein is localized on
peripheral terminals of these neurons [3] and can dephosphorylate
adenine nucleotides at acidic pH, PAP could metabolize pain-
producing ATP and ADP in the inflammatory soup and reduce
the subsequent sensitization of nociceptive neurons. This is
consistent with our observation that PAP2/2 mice show enhanced
thermal hyperalgesia and mechanical allodynia following inflam-
mation [3].
In addition, PAP is localized on the central terminals of
nociceptive neurons [3] and could metabolize nucleotides to
adenosine in a pH-dependent manner at central synapses. The pH
of synaptic vesicles is 5.660.7 [30] and intense neural activity can
lead to acidosis within synapses that lasts for seconds [23].
Likewise, inflammation, tissue injury and repetitive stimulation
cause acidosis of up to 0.25 pH units in the dorsal horn of spinal
cord when measured with pH-sensitive microelectrodes
[31,32,33]. Considering the size of these microelectrodes relative
to the small volume of a synapse, these microelectrode recordings
likely underestimate the magnitude of the pH change that occurs
within the confines of a synapse. Thus, PAP may be exposed to
low extracellular or endosomal pH when spinal synapses are
activated for sustained periods of time.
Intrathecal injection of mPAP produced dose-dependent, potent
and long-lasting (3 days) antihyperalgesic effects that were specific
for the thermal modality in uninjured animals (Fig. 5) and
antihyperalgesic and antiallodynic effects in CFA-inflamed
animals (Fig. 6). Likewise, hPAP and bPAP had similar
antinociceptive effects lasting three days and two days, respectively
[3]. And, just like hPAP and bPAP mediated antinociception, A1R
receptor activation was required for mPAP mediated antinocicep-
tion. When combined with our biochemical results, this suggests
that mPAP converts extracellular nucleotides to adenosine in vivo.
Moreover, these data suggest a species-conserved function for
human, bovine and mouse PAP as an ectonucleotidase.
Adenosine and A1R agonists have potent and, in some studies,
long-lasting (.24 h) analgesic effects in rodents and humans when
injected peripherally or centrally [26,34,35]. However, adenosine
and A1R agonists are not used clinically to treat chronic pain
because of side-effects, including transient lower back pain [36,37],
and motor paralysis when administered at high doses [26]. Motor
side-effects could be due to widespread expression of A1R
throughout the spinal cord, including relatively high-level
expression in motor neurons [38].
We did not observe motor paralysis at the highest doses of
mouse and human PAP tested, despite the fact that PAP also works
via A1R activation (Figs. 5, 6) [3]. This could be due to the fact
that, as an enzyme, the amount of adenosine produced by PAP is
limited by substrate concentration. Thus, through catalytic
restriction, PAP may produce sufficient amounts of adenosine to
mediate antinociception but not enough adenosine to cause overt
motor side-effects.
The resting CSF concentration of AMP in humans is 1.8 mM
[39], well below the Km of mPAP and hPAP for AMP. Since this
AMP concentration is below Km, PAP could produce linear
increases in adenosine as the extracellular AMP concentration
increases. This would allow PAP to dynamically generate
adenosine over a wide range of nucleotide concentrations. This
could be relevant in chronic pain states where extracellular
nucleotides are likely to be elevated [40,41].
Recombinant proteins, such as human growth hormone and
interferons, are routinely used to treat a variety of human diseases
and disorders [11,12]. We found that recombinant mPAP protein
functions as a pH-dependent ectonucleotidase and has antinoci-
ceptive effects in an animal model of inflammatory pain. Unlike
direct injections of adenosine and A1R agonists which produce
antinociception and motor side effects, mPAP injections indirectly
elevate adenosine levels and produce antinociception without side-
effects. Interestingly, other methods that indirectly elevate
adenosine, such as using adenosine kinase inhibitors, also produce
antinociception without motor side effects [42,43,44,45]. Consid-
ering how readily recombinant mPAP and hPAP can be purified
[9], and the fact that recombinant hPAP (fused to GM-CSF; also
known as PA2024, a component of the Provenge/Sipuleucel-T
immunotherapy) is safe to use in humans [10,46], recombinant
PAP could be developed as a protein-based therapeutic for chronic
pain. Moreover, it might be possible to further optimize PAP
stability and kinetic parameters for therapeutic purposes, using
site-directed mutagenesis and the PAP three-dimensional structure
as a guide [9,14,15,47].
Materials and Methods
Molecular biology and protein purification
The mPAP-Tr-(His)6 baculovirus expression clone (encompass-
ing nt 61–1206 from GenBank accession # NM_019807) was
generated by PCR amplification, using a full-length expression
construct of mPAP (secreted isoform) as template and Phusion
polymerase. PCR products were cloned into pFastBac1 (Invitro-
gen) and completely sequenced. Primer sequences contained XbaI
sites (underlined) to facilitate cloning (N-terminal primer: 59-
cgctctagaaccatgcgagccgttcctctgc. C-terminal thrombin-(His)6 tag
primer: 59-gcgtctagattaatgatgatgatgatgatgggagccacgcggaaccagatt-
ccgtccttggtggctgc). There are no thrombin cleavage sites in the
mPAP protein except for the cleavage site we introduced. This
vector was then used to generate recombinant mPAP protein using
the Bac-to-Bac Baculovirus Expression System (Invitrogen).
Briefly, we infected Hi5 insect cells with high-titer recombinant
baculovirus, incubated the cells for 48 hours at 27uC, then
harvested and concentrated the supernatant containing secreted
mPAP protein. Then, mPAP protein was purified from the
concentrated supernatant using Ni-NTA HisTrap agarose (GE
Healthcare Life Sciences) affinity chromatography and imidazole
as eluant. Lastly, mPAP protein was dialyzed against PBS to
remove imidazole. Protein purity was confirmed by SDS-PAGE,
staining for total protein with GelCode Blue (Pierce/Thermo
Scientific, Cat. # 24590) and western blotting with Penta-His
antibody (Qiagen, Cat. # 34660). Amersham full-range rainbow
molecular weight markers (GE Healthcare) were used for SDS-
PAGE and MagicMark XP markers (Invitrogen, Cat. # LC5602)
were used for western blots. This purification strategy is based on
the observation that recombinant rat PAP is secreted into the
medium of baculovirus-infected insect cells [8]. Recombinant
mPAP was kept at 4uC for short-term (1–2 months) use and at
280uC for long-term storage.
Enzyme assays
Enzymatic reactions (50 mL final) were carried out with
recombinant mPAP at 37uC for 3 minutes in 10 mM sodium
acetate, pH 5.6 or 10 mM HEPES, pH 7.0 with AMP, ADP or
ATP as substrate. Reactions were stopped by adding 950 mL of
the malachite green color reagent [0.03% (w/v) malachite green
oxalate, 0.2% (w/v) sodium molybdate, 0.05% (v/v) Triton X-
100, dissolved in 0.7 M HCl] then incubating at room
temperature for 30 minutes. Inorganic phosphate was quantified
by measuring OD650 and comparing to an inorganic phosphate
(KH2PO4) standard curve [48].
Enzyme activity of mPAP was determined using 4-nitrophenyl
phosphate as substrate following Sigma’s Quality Control Test
Antinociceptive Effects of PAP
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Procedure for PAP (SSPNPP11, revision 8/29/97). Unit (U)
definition: 1 U hydrolyzes 1 mmole of 4-nitrophenyl phosphate
per minute at 37uC at pH 4.8.
Cell culture and histochemistry
HEK 293 cells were cultured and transfected as previously
described [3]. Enzyme histochemistry was performed as previously
described [3] using 6 mM AMP, ADP, or ATP as substrate and
Tris-maleate buffer at pH 5.6 or 7.0.
Behavior
All behavioral experiments involving vertebrate animals were
approved by the Institutional Animal Care and Use Committee at
the University of North Carolina at Chapel Hill.
C57BL/6 male mice, 2–4 months old, were purchased from
Jackson Laboratories and used for all behavioral experiments. All
mice were acclimated to the testing room, equipment and
experimenter for at least three days before behavioral testing.
The experimenter was blind to drug treatment during behavioral
testing.
Thermal sensitivity was measured by heating one hindpaw with
a Plantar Test apparatus (IITC) following the Hargreaves method
[49]. The radiant heat source intensity (Plantar test apparatus,
IITC) was calibrated so that a paw withdrawal reflex was evoked
in ,10 s., on average, in wild-type C57BL/6 mice. Cutoff time
was 20 s. One measurement was taken from each paw per time
point to determine paw withdrawal latency. Mechanical sensitivity
was measured using semi-flexible tips attached to an Electronic
von Frey apparatus (IITC) as described elsewhere [50,51]. Three
measurements were taken from each paw (separated at 10 min
intervals) then averaged to determine paw withdrawal threshold in
grams. To induce inflammatory pain, 20 mL Complete Freunds
Adjuvant (CFA, from MP Biomedicals) was injected into one
hindpaw, centrally beneath glabrous skin, with a 30G needle. 8-
cyclopentyl-1, 3-dipropylxanthine (C101, Sigma) was dissolved in
0.9% saline containing 5% DMSO, 1.25% 1 M NaOH for i.p.
injection. Sedation and motor dysfunction were assessed by
visually observing motor activity following injections. None of
the mPAP-injected mice displayed reduced mobility or paralysis
following injection.
Intrathecal injections
We used concentrated mPAP protein (in PBS; 1.1 mg/mL;
400 U/mL) or diluted mPAP (in 0.9% saline) for injections. mPAP
was heat-inactivated by incubating at 65uC for 40 min. Loss of
activity was confirmed using the EnzChek Phosphatase Assay Kit
(Invitrogen, E12020) following the manufacturer’s protocol. Active
or heat-inactivated mPAP was intrathecally injected (5 mL) into
unanesthetized mice using the direct lumbar puncture method [52].
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